ArticleBioconjugate chemistry2026
De Novo Lipid Switch Design for Reactive Oxygen Species-Triggered Liposomal Release.
Article in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Liposomal nanocarriers are highly effective for drug delivery, since they shield encapsulated therapeutic cargo and enhance cellular infiltration. However, a drawback of liposomal carriers involves the limited release of contents after delivery. As such, stimulus-responsive liposomes harnessing synthetic lipid switches that trigger cargo release upon encountering disease-associated conditions have the potential to address this issue. Reactive oxygen species (ROS) have emerged as prominent target stimuli because of their upregulation in diseased cells. Lipid switches designed for liposome release are often derived from phospholipid precursors, an approach that suffers from high expense and hinders scalability because of the limited availability of phospholipids. To address this issue, we report the design and synthesis of an ROS-responsive lipid switch from first principles that does not utilize phospholipid precursors. This culminated in a scalable nonphospholipid switch that forms stable liposomes yet undergoes clean, H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.